Nuvectis Pharma (NVCT) said Friday it closed its public offering of 2.7 million shares, with the underwriter exercising in full the option to buy 405,000 additional shares at $5 per share, boosting gross proceeds to about $15.5 million.
The company said it expects to use the net proceeds from the offering to continue clinical development of its NXP800 and NXP900 product candidates, hire additional personnel, and for capital expenditures and other general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.